Clarivate sells Life Sciences & Healthcare segment to Altaris for $600M

CLARIVATE PLC

Deal value $600M: $500M cash at close, $25M deferred cash, $75M seller note.
Proceeds to reduce debt; transaction expected to close by end of 2026.
Reaffirms FY2026 outlook; LS&H to be classified as discontinued ops from Q3.
Expects non-cash goodwill impairment of $225-250M on LS&H segment.
Company sharpens focus on Academia & Government and Intellectual Property segments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.